** Shares of telehealth firm WW International WW.O rise 8.5% to $41.50 premarket
** Co, also known as WeightWatchers, reports its clinical subscription revenue rose 55.1% during the quarter ended June 30, driven by compounded semaglutide subscriptions
** Says from May 22, it began transitioning subscribers from compounded semaglutide to FDA-approved medications, in line with current FDA guidance
** Co, forecasts 2025 total revenue to be in the range of $685 million to $700 million
** Forecasts adj. core profit to be in the range of $140 million to $150 million
** Co has not previously provided a forecast for 2025
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.